CNS Pharmaceuticals, Inc.
CNSP
$4.59
-$0.30-6.14%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 30.75% | 65.76% | -23.65% | -11.99% | -1.76% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.70% | 87.07% | -42.20% | -4.70% | 22.36% |
| Operating Income | -14.70% | -87.07% | 42.20% | 4.70% | -22.36% |
| Income Before Tax | -14.78% | -87.50% | 42.59% | 6.16% | -21.34% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -14.78% | -87.50% | 42.59% | 6.16% | -21.34% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.78% | -87.50% | 42.59% | 6.16% | -21.34% |
| EBIT | -14.70% | -87.07% | 42.20% | 4.70% | -22.36% |
| EBITDA | -14.68% | -87.09% | 42.21% | 4.71% | -22.36% |
| EPS Basic | 61.43% | 72.66% | 96.24% | -- | -- |
| Normalized Basic EPS | 61.43% | 72.65% | 96.24% | -- | -- |
| EPS Diluted | 61.43% | 72.66% | 96.24% | -- | -- |
| Normalized Diluted EPS | 61.43% | 72.65% | 96.24% | -- | -- |
| Average Basic Shares Outstanding | 197.62% | 585.81% | 1,427.05% | -- | -- |
| Average Diluted Shares Outstanding | 197.62% | 585.81% | 1,427.05% | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |